{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104587","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.705354+00:00","generated_at":"2026-05-17T17:50:31.979393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PMV Pharma Q2 net loss $21.2M; cash $148.3M; Phase 2 interim analysis webinar Sept 10","bullets":["Net loss $21.2M for Q2 2025 vs $1.2M in Q2 2024, due to prior-year $16.2M tax benefit from NOL sale.","Cash, equivalents, and marketable securities $148.3M as of June 30, 2025, expected runway to end of 2026.","R&D expenses $18.4M (up 26% YoY) driven by contractual research costs for rezatapopt program.","Investor webinar Sept 10 to review Phase 2 PYNNACLE interim data; ~65 patients, ~45% ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104587","json":"https://secwatch.observer/filing/0000950170-25-104587.json","markdown":"https://secwatch.observer/filing/0000950170-25-104587.md","text":"https://secwatch.observer/filing/0000950170-25-104587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/0000950170-25-104587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:50:31.979393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}